Intermittent Androgen Deprivation Therapy: Conventional Wisdom versus Evidence

European Urology

Volumn 55, Issue 6, 2009, Pages 1278-1280

  Tombal, Bertrand ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADVERSE OUTCOME; ALLOPATHY; ANDROGEN DEPRIVATION THERAPY; ANIMAL MODEL; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL PRACTICE; COMORBIDITY; DRUG INTERMITTENT THERAPY; EDITORIAL; HOT FLUSH; HUMAN; NONHUMAN; OSTEOLYSIS; OVERALL SURVIVAL; PLACEBO EFFECT; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SEXUAL FUNCTION; TESTOSTERONE BLOOD LEVEL; THERAPY EFFECT; TREATMENT OUTCOME; TUMOR VOLUME;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PATIENT SELECTION; PROGNOSIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 65049088793     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.03.010     Document Type: Editorial

References (10)

1. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
2. Galbraith J. The concept of the conventional wisdom. The Affluent Society (1958), Hamish Hamilton, London, UK p. 6-17
3. Calais da Silva F.E.C., Bono A.V., Whelan P., et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 55 (2009) 1269-1277
4. Akakura K., Bruchovsky N., Goldenberg S.L., Rennie P.S., Buckley A.R., and Sullivan L.D. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 71 (1993) 2782-2790
5. Bhandari M.S., Crook J., and Hussain M. Should intermittent androgen deprivation be used in routine clinical practice?. Clin Oncol 23 (2005) 8212-8218
6. Bruchovsky N., Klotz L., Crook J., Phillips N., Abersbach J., and Goldenberg S.L. Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin Genitourin Cancer 6 (2008) 46-52
7. Higano C., Shields A., Wood N., Brown J., and Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 64 (2004) 1182-1186
8. Hussain M., Tangen C.M., Higano C., et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24 (2006) 3984-3990
9. Salonen A.J., Viitanen J., Lundstedt S., Ala-Opas M., Taari K., and Tammela T.L. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation. J Urol 180 (2008) 915-919 discussion 919-20
10. Studer U.E., Whelan P., Albrecht W., et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24 (2006) 1868-1876